Last reviewed · How we verify
TAK-881
TAK-881 is a selective, potent, and orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
TAK-881 is a selective, potent, and orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | TAK-881 |
|---|---|
| Also known as | Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20), Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20), Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase. |
| Sponsor | Takeda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TAK-881 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to improve glycemic control and reduce the risk of cardiovascular events.
Approved indications
- Type 2 diabetes
- Chronic kidney disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (PHASE2, PHASE3)
- A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (PHASE3)
- A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults (PHASE1)
- A Study of TAK-881 and HyQvia in Healthy Adults (PHASE1)
- A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (PHASE3)
- Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
- A Study of TAK-881 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |